BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $25.00 by Analysts at Citizens Jmp

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price reduced by Citizens Jmp from $27.00 to $25.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Evercore ISI reissued an “in-line” rating and set a $8.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 8th. Barclays reduced their price objective on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, TD Cowen started coverage on BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.33.

BioCryst Pharmaceuticals Trading Up 6.1%

Shares of BCRX stock opened at $7.17 on Wednesday. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The stock’s 50-day moving average price is $7.50 and its 200-day moving average price is $8.68. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -39.83 and a beta of 1.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BCRX. Wealth Enhancement Advisory Services LLC grew its stake in BioCryst Pharmaceuticals by 113.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 20,043 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $79,000. Cerity Partners LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 203.6% in the 1st quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company’s stock worth $273,000 after buying an additional 24,418 shares during the period. CWM LLC increased its stake in shares of BioCryst Pharmaceuticals by 167.5% during the first quarter. CWM LLC now owns 53,750 shares of the biotechnology company’s stock valued at $403,000 after buying an additional 33,656 shares during the period. Finally, Hussman Strategic Advisors Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at $2,362,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.